Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Oncogene|May 10, 2022
Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinomaRussell Moser, Kay E Gurley, Olga Nikolova, et al.Transplantation|December 1, 1993
Induction of tolerance to heart allografts in rats using posttransplant total lymphoid irradiation and anti-T cell antibodiesS L Woodley, K E Gurley, S L Hoffmann, et al.Molecular Cancer Therapeutics|January 29, 2021
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaShogo Shigeta, Goldie Y L Lui, Reid Shaw, et al.Plos One|May 19, 2011
Plasma proteome profiles associated with inflammation, angiogenesis, and cancerKaren S Kelly-Spratt, Sharon J Pitteri, Kay E Gurley, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Functional kinomics identifies candidate therapeutic targets in head and neck cancerRussell Moser, Chang Xu, Michael Kao, et al.Cancer Research|June 10, 2011
Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progressionSharon J Pitteri, Karen S Kelly-Spratt, Kay E Gurley, et al.Nature|November 4, 2014
The mutational landscapes of genetic and chemical models of Kras-driven lung cancerPeter M K Westcott, Kyle D Halliwill, Minh D To, et al.Cell Reports|May 6, 2014
CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancerChristopher J Kemp, James M Moore, Russell Moser, et al.Journal of Proteome Research|August 23, 2007
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancerJeffrey R Whiteaker, Heidi Zhang, Lei Zhao, et al.Ebiomedicine|September 14, 2020
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y L Lui, Reid Shaw, Franz X Schaub, et al.Pageof 6